Celgene/Acceleron win speedy FDA review for luspatercept in beta thalassemia; Korean investor out to shake up Aurinia's board
→ As hoped, Celgene $CELG and its partners at Acceleron $XLRN have secured priority review for their red blood cell boosting drug, luspatercept, which has been pegged to eventually generate peak sales of $2 billion. The biologic has been developed to manage anemia resulting from myelodysplastic syndrome (MDS) as well as beta thalassemia. The FDA expects to make its decision on the beta-thalassemia indication by December 4, while the MDS indication will be dealt with by April 4, 2020. The European review of the drug is also underway, the companies said on Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.